Patient | Sex | Age | Years since primary^{a} | Stage^{b} | Site of metastasis | Prior therapy | Specificity of T-cell response analysed | |
---|---|---|---|---|---|---|---|---|
1 | BRU 1 | F | 57 | 23 | III | LN^{c} | Surgery, vaccination | CMV |
2 | BRU 3 | F | 55 | 6 | IV | LN, lung, spleen | Surgery, vaccination | CMV |
3 | BRU 4 | M | 31 | 3 | III | LN | Surgery, chemotherapy, vaccination | CMV |
4 | BRU 6 | M | 17 | 4 | IV | LN, liver, lung | Surgery, IFN-α, vaccination | CMV |
5 | GE 3 | M | 57 | 1 | IV | LN, liver, lung | Surgery, vaccination | CMV |
6 | GE 4 | M | 55 | 0.5 | IV | LN, lung, skin | Surgery, vaccination | CMV |
7 | GE 5 | M | 55 | 0.5 | IV | LN, intestine | Surgery | CMV |
8 | LAU 18 | F | 73 | 3 | III | LN | Surgery, isolated limb perfusion | Melan-A |
9 | LAU 50 | M | 65 | 2 | III | LN | Surgery, chemotherapy, isolated limb perfusion | Melan-A |
10 | LAU 56 | M | 41 | 10 | III | LN | Surgery, chemotherapy, isolated limb perfusion | Melan-A |
11 | LAU 97 | M | 59 | 5 | III | LN | Surgery, chemotherapy, IFN-α | Melan-A, CMV |
12 | LAU 119 | F | 73 | 5 | III | LN | Surgery | Melan-A |
13 | LAU 132 | M | 33 | 4 | IV | LN, skin | Surgery, IFN-α, vaccination | Melan-A, CMV |
14 | LAU 155 | M | 56 | 5 | IV | LN, liver | Surgery, chemotherapy, IFN-α | Melan-A, CMV |
15 | LAU 156 | M | 46 | 17 | IV | LN, liver, lung | Surgery | Melan-A, CMV |
16 | LAU 169 | M | 52 | 0.5 | IV | LN, skin | Surgery, chemotherapy, IFN-α | Melan-A |
17 | LAU 181 | F | 41 | 0.5 | IV | LN | Surgery | Melan-A |
18 | LAU 198 | F | 70 | 3 | III | LN | Surgery, chemotherapy | Melan-A |
19 | LAU 203 | F | 67 | 5 | III | LN | Surgery | Melan-A, CMV |
20 | LAU 211 | M | 80 | 0.5 | IV | LN, skin | Surgery | Melan-A, CMV |
21 | LAU 212 | F | 69 | 10 | III | LN | Surgery | Melan-A |
22 | LAU 233 | F | 76 | 1 | III | LN | Surgery | Melan-A |
23 | LAU 240 | M | 65 | 1 | III | LN | Surgery | Melan-A |
24 | LAU 241 | M | 49 | 1 | I/II | Surgery | CMV | |
25 | LAU 253 | M | 63 | 2 | III | LN | Surgery | Melan-A |
26 | LAU 258 | F | 65 | 7 | III | LN | Surgery | CMV |
27 | LAU 267 | M | 45 | 1 | III | LN | Surgery, IFN-α | Melan-A |
28 | LAU 269 | M | 23 | 2 | III | LN | Surgery, isolated limb perfusion | Melan-A |
29 | LAU 306 | M | 58 | 0.5 | III | LN | Surgery | Melan-A |
30 | LAU 321 | M | 64 | 5 | IV | LN, lung | Surgery | Melan-A |
31 | LAU 337 | F | 25 | 3 | IV | LN, lung, skin | Surgery, IFN-α, vaccination | Melan-A |
32 | LAU 343 | M | 78 | 1 | III | LN | Surgery | Melan-A |
33 | LAU 350 | M | 63 | 0.5 | III | LN | Surgery | Melan-A |
34 | LAU 352 | M | 77 | 2 | III | LN | Surgery, vaccination | Melan-A |
35 | LAU 359 | M | 61 | 1 | III | LN | Surgery, vaccination | Melan-A |
36 | LAU 362 | F | 59 | 2 | IV | LN, skin | Surgery | Melan-A, CMV |
37 | LAU 372 | M | 59 | 0 | III | LN | Surgery | Melan-A |
38 | LAU 387 | F | 59 | 3 | IV | LN, skin | Surgery, IFN-α | CMV |
39 | LAU 390 | F | 38 | 1 | III | LN | Surgery, chemotherapy, IFN-α | CMV |
40 | LAU 392 | F | 33 | 4 | III | LN | Surgery | Melan-A |
41 | LAU 435 | M | 67 | 4 | III | LN | Surgery | Melan-A |
42 | LAU 441 | M | 64 | 1 | III | LN | Surgery | CMV |
43 | LAU 444 | F | 31 | 3 | IV | LN, skin | Surgery | Melan-A |
44 | LAU 450 | F | 72 | 2 | IV | LN, skin, brain | Surgery, vaccination | Melan-A |
45 | LAU 455 | M | 56 | 20 | IV | LN, lung | Surgery, chemotherapy | Melan-A |
46 | LAU 460 | F | 61 | 7 | IV | LN, skin | Surgery, chemotherapy, vaccination | CMV |
47 | LAU 465 | M | 48 | 6 | III | LN | Surgery | Melan-A |
48 | LAU 498 | F | 60 | 1 | III | LN | Surgery, vaccination | CMV |
49 | LAU 529 | M | 63 | 3 | IV | LN, lung | Surgery, chemotherapy, vaccination | CMV |
50 | LAU 552 | F | 35 | 1 | IV | LN, skin | Surgery, IFN-α | CMV |
51 | LAU 562 | M | 55 | 5 | IV | LN, skin | Surgery, IFN-α | CMV |
52 | LAU 567 | F | 54 | 0.5 | III | LN | Surgery, vaccination | Melan-A, CMV |
53 | LAU 576 | M | 57 | 0 | III | LN | Surgery | Melan-A |
54 | LAU 608 | F | 66 | 5 | IV | LN, skin | Surgery, isolated limb perfusion | CMV |
55 | LAU 622 | M | 66 | 2 | IV | LN, lung, skin | Surgery | Melan-A |
56 | LAU 640 | F | 58 | 0.5 | IV | LN, skin | Surgery | Melan-A |
57 | LAU 651 | F | 45 | 0.5 | IV | LN, skin | Surgery | Melan-A |
58 | LAU 653 | M | 56 | 3 | IV | LN, skin | Surgery, isolated limb perfusion | Melan-A |
59 | LAU 671 | F | 57 | 0 | III | LN | Surgery | CMV |
60 | LAU 709 | F | 43 | 7 | III | LN | Surgery, vaccination | CMV |
61 | MEL 162 | M | 60 | 2 | III | LN | Surgery, chemotherapy, IFN-α | Melan-A |
^{a} Years elapsed between excision of primary lesion and sample studied.
^{b} American Joint Committee on Cancer staging system.
^{c} LN, lymph node; CMV, cytomegalovirus.